GlobalData on MSN15d
Acadia submits MAA to EMA for Rett syndrome therapyAcadia Pharmaceuticals has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for ...
Acadia Pharmaceuticals ACAD announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval for trofinetide to treat Rett syndrome ...
Neuren Pharmaceuticals (ASX:NEU) has announced that its partner Acadia Pharmaceuticals has submitted a Marketing ...
Acadia Pharmaceuticals (ACAD) announced that the company has submitted a marketing authorization application to the European Medicines Agency ...
Acadia Pharma seeks European marketing approval for trofinetide for the treatment of Rett syndrome: San Diego Thursday, January 16, 2025, 13:00 Hrs [IST] Acadia Pharmaceuticals In ...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for trofinetide for the ...
Stockhead on MSN15d
Health Check: Biotech partnership eyes Euro market expansion for Rett syndrome drugNeuren Pharmaceuticals (ASX:NEU) has announced that its partner, Nasdaq-listed Acadia Pharmaceuticals, has submitted a ...
Acadia Pharmaceuticals has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for trofinetide, aimed at treating Rett syndrome in adults and in children ...
Acadia Pharmaceuticals ACAD announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval for trofinetide to treat Rett ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback